WO2020011938A1 - Glucocorticoïdes pour le traitement topique de la gastrite auto-immune - Google Patents

Glucocorticoïdes pour le traitement topique de la gastrite auto-immune Download PDF

Info

Publication number
WO2020011938A1
WO2020011938A1 PCT/EP2019/068718 EP2019068718W WO2020011938A1 WO 2020011938 A1 WO2020011938 A1 WO 2020011938A1 EP 2019068718 W EP2019068718 W EP 2019068718W WO 2020011938 A1 WO2020011938 A1 WO 2020011938A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
patient
glucocorticoid
gastric
stomach
Prior art date
Application number
PCT/EP2019/068718
Other languages
English (en)
Inventor
Elisabeth ORGLER
Christoph Gasche
Stefanie DABSCH
Original Assignee
Medizinische Universität Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universität Wien filed Critical Medizinische Universität Wien
Publication of WO2020011938A1 publication Critical patent/WO2020011938A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to compositions comprising one or more glucocorticoid(s) used in the topical treatment of autoimmune gastritis by delivering an effective amount of the glucocorticoid(s) to the topical area to be treated using a controlled release drug delivery system that releases the glucocorticoid(s) in a timely and locally controlled manner.
  • the topical area to be treated comprises or is the mucosa of the stomach, preferably the mucosa of the corpus and/or fundus of the stomach and the preferred glucocorticoid is budesonide.
  • Autoimmune gastritis is a chronic inflammatory disease of the stomach occurring in up to 8% of the general population and, as the name implies, is characterized by atrophy of the glands in the corpus mucosa caused by the cells of the body's own immune defense system, i.e. with the development of autoantibodies against parietal cells of the gastric body (Toh 2014).
  • PCA parietal cell autoantibodies
  • Parietal cells are epithelial cells located in the glands of the corpus and fundus but not in the antrum and produce hydrochloric acid and intrinsic factor (Kulnigg-Dabsch 2016).
  • the acidification of the stomach is primarily managed by the gastritic H+/K+ ATPase, the proton pump, which is impaired in AIG (Toh et al, 2000).
  • the decrease and final loss of the parietal cells during progression of the disease results in increased pH of the stomach and loss of intrinsic factor produced by parietal cells.
  • Intrinsic factor is required for uptake of vitamin B I2 . Consequently, vitamin B I2 deficiency is a known result of AIG (Kulnigg-Dabsch 2016).
  • AIG is often associated with impaired absorption of vitamin B I2 and possibly other vitamin and mineral deficiencies, such as folate, and iron deficiency.
  • Patients who developed vitamin B I2 deficiency will suffer from gastrointestinal and neurological complaints such as malabsorption, diarrhea, weight loss, glossitis, peripheral numbness, paresthesia with subsequent development of weakness, and ataxia (Kulnigg-Dabsch 2016).
  • the Sydney System differentiates between the atrophic gastritis of types A and B, wherein AIG is referred to the“A type” gastritis recognized as a corpus- restricted atrophic gastritis of autoimmune origin, and the“B type” represents the atrophic gastritis that is related to H.pylori infection (Dixon et al, 1996; Sipponen and Price, 2011).
  • the group of H. pylori-associated gastritis can be further subdivided into forms of gastritis whose morphological distribution patterns usually identify them as sequelae of H. pylori infection, while the group of gastritis unassociated with H.
  • pylori can be differentiated into autoimmune, chemically induced reactive gastritis, ex-H. pylori gastritis, Helicobacter heilmannii gastritis, Crohn's gastritis and a number of special forms of gastritis. (Stolte et al, 2001).
  • AIG does not cause any obvious signs and symptoms. However, some people may experience nausea, vomiting, a feeling of fullness in the upper abdomen after eating, or abdominal pain. The main manifestation of AIG is known to be pernicious anemia.
  • the clinical signs and symptoms of anemia include shortness of breath, dizziness, tachycardia, lightheadedness, and decreased cognitive and physical function (Kulnigg-Dabsch 2016).
  • ID iron deficiency
  • ID amenia a nutritional deficiency caused by an imbalance of iron uptake and iron loss and affecting about 10 to 30 % of women in industrialized nations being in reproductive age.
  • ID is either caused by increased loss of iron due to acute or chronic bleeding, such as gastrointestinal bleeding, augmented menstrual bleeding, or by low absorption of iron.
  • Decreased iron absorption might be due to inflammation at the site of iron uptake, which is found in AIG, wherein the decrease of gastric acid and ascorbic acid contributing to the release of iron-protein-complexes and to reduction of ferric iron are well described (Hershko et al (2007); Aditi et al, (2012)). Symptoms of ID arise independently of amenia-related symptoms, and include fatigue, restless legs syndrome, brittle nails, hair loss, impaired immune function, and impaired wound healing.
  • AIG is considered a "precancerous" condition and it may be responsible for the development of gastric adenocarcinoma or carcinoids.
  • a precursor lesion may be induced by the chronic inflammation in AIG patients which may first lead to atrophy of the tissue in the fundus and/or the corpus and subsequently to intestinal metaplasia (Kulnigg-Dabsch 2016).
  • Development of gastric cancer is also known from H.
  • pylori-related gastritis wherein a major characteristic of the infiltration with inflammatory cells is the typically severe corpus gastritis (Kulnigg-Dabsch 2016; Stolte et al., 2001).
  • AIG patients it is also surmised that unknown genetic, metabolic, or environmental triggers may lead to the adenocarcinoma, which is also known from colonic cancer (Correa 1988).
  • AIG autosomal dominant manner
  • Patients suffering from AIG are likely to have other autoimmune disorders including autoimmune thyroiditis, diabetes type I, Addison’s disease, and vitiligo.
  • Diagnosis of AIG is made through a combination of clinical findings, such as certain blood tests and presence of other autoimmune conditions, and the collection of a biopsy of fundus and/or corpus obtained through endoscopy (Kulnigg-Dabsch 2016). Treatment is based on the signs and symptoms present in each person, but may include iron infusions, vitamin B I2 injections and endoscopic surveillance (Park et al, 2013; Kulnigg-Dabsch 2016).
  • vitamin B I2 injections may be recommended. Iron therapy approaches may include receiving periodic intravenous iron infusion to increase iron stores or a daily dose of oral ferrous glycine sulfate to meet daily iron requirements. In this context, it is recommended that levels of B I2 and iron are routinely monitored in patients suffering from and having suffered from AIG. In some cases, periodic endoscopy may also be recommended due to the increased risk of certain types of cancer (Park et al., 2013; Kulnigg-Dabsch 2016). Despite symptomatic treatment of AIG based on iron infusions, vitamin ! injections and endoscopic surveillance, there is no curative treatment for autoimmune gastritis at this moment.
  • pernicious anaemia can be alleviated by vitamin B I2 replacement therapy, but this has no impact on the underlying destructive autoimmune disease process (Toh et al, 2012).
  • the effect of immunosuppression by prednisolone was assessed in a mouse model of autoimmune gastritis. It led to remission of the gastric inflammation during therapy, however, withdrawal promptly results in disease recurrence (Biondo et al, 2006).
  • treatment of AIG with glucocorticoid(s) appears not to be recommendable due to the steroid- associated systemic side effects, in particular by long-term administration of systemically effective steroids. Therefore, systemic effects of potential drugs for the treatment of AIG should be avoided, e.g.
  • the objective of the present invention is the provision of an efficient and locally effective treatment for patients having AIG.
  • a suitable drug delivery system may enable a local release of the drug at the topical area to be treated and prolong the retaining ability in the topical area to be treated and would thus improve gastric residence time and efficacy of the drug.
  • the present invention relates to a composition comprising one or more glucocorticoid(s) for use in the topical treatment of a patient having autoimmune gastritis, wherein the topical area to be treated comprises or is the mucosa of the stomach.
  • a method for topical treatment of a patient having autoimmune gastritis comprising administering a composition comprising one or more glucocorticoid(s) to a patient having autoimmune gastritis, wherein the topical area to be treated comprises or is the mucosa of the stomach.
  • composition of the present invention comprises a carrier.
  • the carrier comprises a carrier for oral administration.
  • the herein provided composition comprises a carrier, which is a controlled and a sustained release carrier for delivery of an effective amount of said one or more glucocorticoid(s) to the topical area of the patient having autoimmune gastritis and release of an effective amount of said one or more glucocorticoid(s) at the topical area.
  • the carrier is in the form of an oral suspension or an effervescent tablet or a gel. In particularly preferred aspects, the carrier is in the form of a gel.
  • the carrier releases an effective amount of one or more glucocorticoid(s) at the topical area at a time period between 0 and 15 minutes after onset of topical treatment with said composition.
  • the one or more glucocorticoid(s) is/ are locally effective at the topical area to be treated.
  • autoimmune gastritis in a patient is determined histologically, by the occurrence of gastric inflammation, by the occurrence of destruction of parietal cells, and by a subsequent failure in production of gastric acids, resulting in higher gastrin secretion, and/or increased parietal cell antibody (PCA) and/or anti-intrinsic factor antibody (IFA) levels in a sample of the patient, wherein an increase in PCA or IFA levels and/or a pH increase of gastric juice, compared to a control level is indicative for the patient of having AIG.
  • PCA parietal cell antibody
  • IFA anti-intrinsic factor antibody
  • autoimmune gastritis in a patient is determined by the PCA level in a sample of the patient, wherein a PCA level above 100 U/ml compared to a control level is indicative for the patient of having active AIG.
  • a response to treatment of AIG in a patient is indicated by histological remission, by reduction of gastric inflammation, by suppression of the destruction of parietal cells, by the pH level of gastric juice, specifically serum gastrin, and/or by the PCA and IFA levels, wherein a decrease in PCA/IFA level and/or a decrease of gastric juice pH, specifically reduction in gastrin, compared to a predetermined level or a control is indicative for a response to said treatment.
  • a response to treatment of AIG in a patient is indicated by reduction of the gastric pH level of gastric juice, preferably reduction of the pH level by more than 2.
  • the one or more glucocorticoid(s) is/are selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, beclomethasone, dipropionate, dexamethasone sodium phosphate, fluticasone propionate, hydrocortisone, prednisone, prednisolone, mometasone, tipredane, and butixicort.
  • the glucocorticoide is budesonide.
  • the composition is administered in a dose of: 0.01 mg/ml to 10 mg/ml budesonide, more preferably 0.05 mg/ml to 5.0 mg/ml budesonide, more preferably 0.1 mg/ml to 1.0 mg/ml budesonide.
  • the composition is administered at an interval of every two days, once a day, twice a day or three times a day, more preferably once a day, or twice a day.
  • a delayed stomach emptying of the patient extends the time period of the release of the effective amount of one or more glucocorticoid(s) at the topical area in the patient.
  • oral administration of a liquid to the patient is suitable to control the time period in which the effective amount of one or more glucocorticoid(s) at the topical area is released.
  • an empty stomach of the patient enhances the therapeutic efficacy of the one or more glucocorticoid(s) at the topical area to be treated.
  • the composition further comprises reducing the risk of developing one or more diseases associated with AIG, specifically pernicious anemia (PA), autoimmune metaplastic atrophic gastritis (AMAG), gastric adenocarcinoma or gastric neuroendocrine tumors.
  • AIG pernicious anemia
  • AMAG autoimmune metaplastic atrophic gastritis
  • gastric adenocarcinoma gastric neuroendocrine tumors.
  • composition comprising the one or more glucocorticoid(s) is provided for the topical treatment of patients having AIG, wherein the topical area to be treated comprises or is the mucosa of the stomach.
  • composition and/or method of the present invention relates to a composition comprising one or more glucocorticoid(s) that releases the glucocorticoid(s) in a locally and/or timely controlled manner at the topical area to be treated by using a drug delivery system, particularly a gastroretentive drug delivery system, that delivers the drug at a site-specific area, i.e. the topical area to be treated and/or in a sustained release manner.
  • a drug delivery system particularly a gastroretentive drug delivery system
  • the composition of the present invention comprises a carrier, which is a controlled and/or a sustained release carrier, which is suitable for the delivery of an effective amount of said one or more glucocorticoid(s) to the topical area as outlined above and/or wherein the one or more glucocorticoid(s) are released in a sustained manner and are distributed uniformly at the topical area to be treated.
  • a carrier which is a controlled and/or a sustained release carrier, which is suitable for the delivery of an effective amount of said one or more glucocorticoid(s) to the topical area as outlined above and/or wherein the one or more glucocorticoid(s) are released in a sustained manner and are distributed uniformly at the topical area to be treated.
  • the therapeutic efficacy of the treatment of AIG by the composition of the present invention can be further controlled by considering the physiological condition of the stomach of the patient.
  • the duration of the sustained release of glucocorticoid(s) may be extended due to a delayed stomach emptying of the patient and/or controlled by administration of a particular amount of liquid to the patient.
  • the administration of liquid to the patient may further control the local distribution of the composition comprising the one or more glucocorticoid(s) at the topical area to be treated.
  • the therapeutic efficacy of the one or more glucocorticoid(s) may be enhanced by an empty stomach of the patient at the topical area to be treated as the glucocorticoid(s) of the composition do not interfere with contents in the stomach such as food, thereby facilitating the contact and adsorption of the one or more glucocorticoid(s) the topical area to be treated, i.e. the mucosa of the stomach, preferably the mucosa of the corpus and the fundus.
  • Delayed stomach emptying is a common symptom of AIG.
  • a delayed stomach emptying of the patient may extend the time period of the release of the effective amount of one or more glucocorticoid(s) at the topical area to be treated in the patient.
  • the longer residence time in the stomach may be advantageous for the sustained local action of the glucocorticoid(s), wherein a consistent effective amount of glucocorticoid(s) without overdosing may be readily released in a timely controlled manner.
  • glucocorticoid(s) that are absorbed readily upon release in the stomach may have an improved bioavailability and therapeutic efficacy.
  • the terms“autoimmune gastritis” and“AIG” are used interchangeably and refer to a chronic inflammatory disease of the stomach with destruction of parietal cells of the gastric body and fimdus that may lead to the atrophy of the mucosa.
  • the terms“parietal cells autoantibodies” and“PCA” are used interchangeably and refer to autoantibodies which are directed against parietal cells of the gastric body and fundus but not in the antrum of the stomach and induce destruction of such by autoimmunity.
  • chronic atrophic gastritis is not synonymous to AIG since the atrophy of the mucosa is the result of a chronic inflammatory disease independent of etiology, which is mainly Helicobacter pylori gastritis or AIG.
  • Autoimmune antibodies in AIG target parietal cells which are located in the corpus and fimdus but not in the antrum.
  • other gastritis diseases such as Helicobacter pylori-, stress-, or drug induced gastritis
  • inflammation and continuous atrophy is restricted to the corpus and the fimdus in AIG.
  • the prevalence of AIG has been estimated to occur in up to 8% of the general population (Toh 2014).
  • AIG is by far more common in women than in men.
  • a majority of diagnosed individuals with the condition are older adults (commonly >60 years of age), although the disease develops at much younger age (between 15 to40 years) but remains asymptomatic.
  • compositions and“pharmaceutical composition” are used interchangeably and are to be understood as defining pharmaceutical compositions of which the individual components or ingredients are themselves pharmaceutically acceptable, e.g. where oral administration is foreseen, acceptable for oral use and, where topical administration is foreseen, topically acceptable and also includes combinations thereof, i.e. where oral and topical administration is foreseen, acceptable for oral and topical use.
  • the pharmaceutical composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient, the site of delivery of the pharmaceutical composition, the method of administration, the scheduling of administration, and other factors known to practitioners.
  • the "effective amount" of the pharmaceutical composition for purposes herein is thus determined by such considerations. The skilled person knows that the effective amount of pharmaceutical composition administered to an individual will, inter alia, depend on the nature of the compound.
  • the composition of the present invention comprises a carrier, which is a controlled and a sustained release carrier for delivery of an effective amount of said one or more glucocorticoid(s) to the topical area of the patient having autoimmune gastritis and release of an effective amount of said one or more glucocorticoids at the topical area.
  • a carrier which is a controlled and a sustained release carrier for delivery of an effective amount of said one or more glucocorticoid(s) to the topical area of the patient having autoimmune gastritis and release of an effective amount of said one or more glucocorticoids at the topical area.
  • the term“effective amount of said one or more glucocorticoid(s)” as used herein refers to the amount of the one or more glucocorticoid(s) that elicits the biological or medicinal response in the patient suffering from AIG, which includes alleviation of the symptoms of the condition being treated.
  • the therapeutically effective amount can be determined using routine optimization techniques and is dependent upon the particular condition to be treated, the condition of the patient suffering from AIG, the route of administration, the formulation, and the judgment of the practitioner and other factors evident to those skilled in the art.
  • delivery of an effective amount of said one or more glucocorticoid(s) refers to a site specific delivery in the stomach, preferably in the fundus and corpus of the stomach. It is obtained by a locally specific and retaining dosage form as provided by the present invention wherein the one or more glucocorticoid(s) are released by a controlled-release carrier.
  • controlled-release carrier includes components of a controlled drug delivery system and refers to a carrier which releases an efficient amount of the active ingredient in a timely and locally controlled manner to specific site(s) of the topical area to be treated for a sufficient length of time.
  • the locally and timely controlled release of the glucocorticoid(s) is achieved by the components included in the composition.
  • the carrier of the present invention allows, e.g., after oral application, the local bio availability of the active substance, i.e. the glucocorticoid(s), preferably budesonide, in a sufficiently high concentration at the site of inflammation, i.e.
  • the mucosa of the stomach preferably the mucus of the fundus and corpus of the stomach.
  • This locally controlled stomach targeting concept is preferably achieved by a slow sliding of the composition along the mucosa of the stomach, preferably the fundus and the corpus of the stomach, associated with complete wetting of the surface as well as adhesion of the glucocorticoid(s) to the mucosa of the stomach, preferably to the mucosa of the fundus and/or the corpus of the stomach.
  • the one or more glucocorticoid(s) of the composition of the present invention are specifically brought to the site of action, i.e. the site of inflammation, and distributed uniformly and completely thereon.
  • the carrier of the present invention for the treatment of AIG is in a dosage form suitable to counteract the inflammatory processes and changes in the stomach, particularly in the fundus and the corpus of the stomach.
  • a carrier of the composition of the present invention may be based on a retaining dosage form which functions through a gastroretentive delivery system.
  • a “gastroretentive delivery system” or “sustained release drug delivery system” are used interchangeably and refer to drug delivery systems with prolonged residence time in the stomach for drugs that i) are locally active in the stomach, ii) have an absorption window in the stomach, and/or iii) are unstable in the small intestinal or colonic environment.
  • kits for treating obesity disorders may exhibit low solubility at high pH values and high solubility at low pH values, such as those pH values found in the stomach of a patient, so that the active ingredient of the composition is specifically dissolved in the stomach.
  • the gastroretentive delivery system of the present invention should have a high solubility at such increased pH values in the stomach of AIG patients, preferably at pH values ranging from pH 5 to pH 7.
  • a controlled release dosage form which remains in the stomach for long periods prolongs the gastric retention time of the composition comprising one or more glucocorticoid(s) so that the drug can be supplied continuously to the absorption site on the stomach.
  • Controlled-release is used herein to describe a method and composition for making an active ingredient available to the biological system of a host as described below in more detail.
  • the method of effecting controlled release can be varied.
  • the active ingredient can be associated physically and/or chemically with a surfactant, a chelating agent, etc.
  • the active ingredient can be masked by a coating, a laminate, etc.
  • the present invention contemplates delivery of a controlled-release system which may utilize one or more of the "release” methods and compositions. Factors that need to be considered in the development controlled release drug delivery systems, e.g.
  • the density of the dosage forms may be decisive for the gastric residence time since dosage forms having a density lower than that of gastric fluids are floating on the gastric contents, thereby increasing the gastric residence time.
  • a large size of the dosage form may increase gastric residence time because a larger size will not allow the dosage form to quickly pass through the pyloric spincter to intestine.
  • Either round or spherical shaped dosage form may exhibit better property related to other shapes.
  • Gastric retention time of the dosage form is less during fasting condition due to rise in gastric motility.
  • high amount of fatty acid and other indigestible polymers slow down the gastric retention time due to variation in gastric motility.
  • the controlled release dosage form of the present may remain in the stomach of an AIG patient for extended periods of time, e.g., due to delayed stomach emptying in these patients.
  • the gastric retention time of the composition comprising one or more glucocorticoid(s) may be prolonged so that the drug may be supplied continuously to the absorption site on the stomach.
  • the composition of the present invention may retain in the stomach, preferably in the fundus and the corpus of the stomach for at least 10 min, preferably for at least 60 min.
  • the amount of liquid in the dosage form may influence the efficacy of the glucocorticoid(s) of the composition in the stomach, preferably the fundus and the corpus of the stomach. In this sense, a sufficient amount of liquid in the dosage form may be required for complete wetting of the surface of the mucosa. Such a uniform distribution of the composition may be advantageous for the local effect of the active ingredients of the composition at the mucosa since the glucocorticoid(s) are released uniformly and completely to their site of action, i.e. the topical area to be treated.
  • the amount of liquid administered in or with the dosage form varies between 2 and 500 ml, preferably between 10 and 100 ml.
  • compositions at the mucosa of the stomach may be additionally supported, e.g. if the patient rests in a lateral position after administration of the composition.
  • glucocorticoid(s) such as budenoside, may be released uniformly and completely at the site of action.
  • the release of the minimum amount of a glucocorticoid, such as budesonide, required for an effective amount to be released only in the stomach may be achieved by various methods, for example by swallowing/taking a tablet, such as an effervescent coated tablet, at an empty stomach stage, followed by immediate uptake of 100 to 300 ml water followed by 20 minutes resting at left lateral position.
  • a tablet such as an effervescent coated tablet
  • the tablet is taken twice a day, preferably every 12 hours.
  • Controlled release delivery systems including gastroretentive delivery systems can be categorized into floating and non-floating systems.
  • the non-floating systems include, for example, swelling, bioadhesive, expendable and high-density systems.
  • Floating Drug Delivery Systems have a bulk density lower than gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, without affecting the gastric emptying rate and the drug is released slowly at a desired rate from the system resulting in an increase in the gastric residence time and a better control of fluctuations in the plasma drug concentrations and after complete release of the drug, the residual system is emptied from the stomach.
  • Effervescent systems comprise gas generating systems and volatile liquid containing systems.
  • the mechanism of the gas generating system is the production of C0 2 gas due to the reaction between sodium bicarbonate, citric acid and tartaric acid.
  • the gas produced by the system is entrapped in swollen hydrocolloids of the system resulting in the reduction of density of the system so that it floats on the gastric fluids.
  • Volatile liquid containing systems have an inflatable chamber which contains a liquid, e.g. ether, cyclopentane, that gasifies at body temperature to cause the inflation of the chamber in the stomach.
  • the non-effervescent floating dosage forms may have swellable cellulose type of hydrocolloids, polysaccharides, and matrix- forming polymers like polycarbonate, polyacrylate, polymeth-acrylate, and polystyrene. It is created by mixing of drug with the gel, followed by swelling by coming in contract with gastric fluid after oral administration and thus maintaining a relative integrity of shape and keeping a density less than one. The dosage form gains its buoyancy owing to air trapped in the swelled up matrix.
  • This swollen up matrix reserves drug and can maintain sustained drug release via gelatinous mass hydroxylpropyl methyl cellulose (HPMC), polyacrylate, polyvinyl acetate, carbopol, agar, sodium alginate, calcium chloride, polyethylene oxide and polycarbonates, which are the most commonly used excipients.
  • HPMC hydroxylpropyl methyl cellulose
  • polyacrylate polyvinyl acetate
  • carbopol agar
  • sodium alginate calcium chloride
  • polyethylene oxide and polycarbonates which are the most commonly used excipients.
  • non-effervescent systems include but are not limited to the raft forming systems and bioadhesive systems. Raft forming systems have received much attention for the delivery of antacids and drug delivery for gastrointestinal infections and disorders.
  • the mechanism involved in the raft formation includes the formation of viscous cohesive gel in contact with gastric fluids, wherein each portion of the liquid swells forming a continuous layer called a raft.
  • This raft floats on gastric fluids because of low bulk density created by the formation of C0 2 .
  • the system contains a gel forming agent and alkaline bicarbonates or carbonates responsible for the formation of C0 2 to make the system less dense and float on the gastric fluids.
  • the system contains a gel forming agent (e.g. alginic acid), sodium bicarbonate and acid neutralizer, which forms a foaming sodium alginate gel (raft) when in contact with gastric fluids.
  • the raft thus formed floats on the gastric fluids and prevents the reflux of the gastric contents (i.e. gastric acid) into the esophagus by acting as a barrier between the stomach and esophagus.
  • Bioadhesive systems bind to the gastric epithelial cell surface or mucus, which extends the retention time of the drug delivery system in the stomach.
  • bioadhesives may be added to the composition of the present invention in order to increase the viscosity of the composition enabling slow sliding along the mucosa and uniform distribution of the glucocorticoid(s) in the stomach, preferably the fundus and the corpus of the stomach.
  • the terms“bioadhesive” and“mucoadhesive” are used interchangeably and refer to any substance that can adhere to a biological substrate and are particularly capable of being retained on that surface for an extended period of time.
  • Bioadhesives can adhere to different substrates; however, bioadhesives generally adhere to membranes or the mucin layer of those membranes.
  • the bioadhesives of the present invention adhere to the mucus of the stomach, preferably the mucus of the fundus and the corpus of the stomach.
  • bioadhesion refers to the state in which two materials, amongst which one is biological in nature, adhere to each other, preferably for extended periods of time with the help of interfacial forces.
  • the term“mucus” refers to a usually clear viscid fluid that may be secreted by mucous membranes in various tissues of the body lining the organs and body cavities, including by the respiratory, gastrointestinal, and reproductive tracts.
  • the epithelial may be either single layered, e.g. the stomach, small and large intestines and bronchi, or multilayered/stratified, e.g. in the esophagus and cornea.
  • the former contain goblet cells which secret mucus directly onto the epithelial surfaces: the latter contain, or are adjacent to tissues containing, specialized glands such as salivary glands that secret mucus onto the epithelial surface.
  • Mucus is present either as a gel layer adherent to the mucosal surface of as a luminal soluble or suspended form.
  • the major components of all mucus gels are mucin glycoproteins, lipids, inorganic salts and water, the latter accounting for more than 95% of their weight, making them a highly hydrated system.
  • adheresion refers to the bond produced by contact between a pressure sensitive adhesive and the surface.
  • adhesive refers to the state in which two surfaces are held together by interfacial forces, which may consist of valence forces, interlocking action or both.
  • the mechanism of bioadhesion is generally divided into two steps: the contact stage and the consolidation stage.
  • the first stage of bioadhesion is characterized by the contact between the bioadhesive and the mucus membrane.
  • the bioadhesive materials are activated by the presence of moisture. Moisture plasticizes the system, allowing the bioadhesive molecules to break free and to link up by weak van der Waals and hydrogen bonds.
  • the controlled release drug delivery system of the present invention may be a bioadhesive controlled release delivery system.
  • the ability to provide adhesion of a drug delivery system to the gastrointestinal wall specifically may provide longer residence time in a particular organ site, thereby producing an improved effect in terms of local action.
  • the one or more glucocorticoid(s) is/ are locally effective at the topical area. Binding of polymers to the mucin/epithelial surface can be divided into three categories: hydration-mediated adhesion, bonding-mediated adhesion and receptor-mediated adhesion.
  • Hydration-mediated adhesion is based on certain hydrophilic polymers that tend to imbibe large amount of water and become sticky, thereby acquiring bioadhesive properties.
  • Bonding- mediated adhesion involves adhesion of polymers to a mucus/epithelial cell surface via various bonding mechanisms, including physical-mechanical bonding and chemical bonding. Physical-mechanical bonds can result from the insertion of the adhesive material into the folds or crevices of the mucosa. Chemical bonds may be either covalent (primary) or ionic (secondary) in nature. Secondary chemical bonds consist of dispersive interactions (i.e., Vander Waals interactions) and stronger specific interactions such as hydrogen bonds. The hydrophilic functional groups responsible for forming hydrogen bonds are the hydroxyl and carboxylic groups.
  • Receptor-mediated adhesion involves certain polymers binding to specific receptor sites on the cell surfaces, thereby enhancing the gastric retention of dosage forms.
  • adhesion occurrs by means of electron transfer between the mucus and the mucoadhesive system, arising through differences in their electronic structures.
  • the electron transfer between the mucus and the mucoadhesive results in the formation of double layer of electrical charges at the mucus and mucoadhesive interface.
  • the net result of such a process is the formation of attractive forces within this double layer.
  • the wetting theory emphasizes the intimate contact between the mucoadhesive polymer and the mucus, and, primarily in liquid systems, it uses interfacial tensions to predict spreading, and subsequent adhesion. Thereby, the wetting theory calculates the contact angle and the thermodynamic work of adhesion.
  • the mucoadhesive molecules and the glycoproteins of the mucus mutually interact by means of interpenetration of their chains and the building of secondary bonds.
  • the mucoadhesive device has features favoring both chemical and mechanical interactions.
  • molecules with hydrogen bond building groups - OH, -COOH
  • an anionic surface charge high molecular weight, flexible chains and surface-active properties, which help in spreading throughout the mucus layer, can present mucoadhesive properties (Hagerstrom et ah, 2003; Boddupalli et ah, 2010).
  • the fracture theory analyzes the force that is required to separation of two surfaces after adhesion. It is considered to be appropriate for the calculation of the fracture strengths of adhesive bonds involing rigid mucoadhesive materials, and has frequently been applied to the analysis of tensile strength measurements on, for example, microspheres and powder specimens.
  • MRI Magnetic resonance imaging
  • bioadhesive drug delivery systems wherein common sites of application where bioadhesive drugs have the ability to deliver pharmacologically active agents include oral cavity, eye conjunctiva, vagina, nasal cavity and gastrointestinal tract (Ahuja et al, 1997).
  • the buccal cavity has a very limited surface area of around 50 cm 2 and is comprised of three distinct layers - epithelium, basement membrane, and connective tissues. Mucus is secreted by salivary glands, as a component of saliva, forming a 0.1-0.7 mm thick layer.
  • the easy access of the buccal cavity makes it a preferred location for delivering active agents.
  • the site provides an opportunity to deliver pharmacologically active agents systemically by avoiding hepatic first- pass metabolism in addition to the local treatment of the oral lesions.
  • the sublingual mucosa is relatively more permeable than the buccal mucosa due to the presence of large number of smooth muscle and immobile mucosa.
  • formulations for sublingual delivery are designed to release the active agent quickly while mucoadhesive formulation is of importance for the delivery of active agents to the buccal mucosa, where the active agent has to be released in a controlled manner.
  • This makes the buccal cavity more suitable for bioadhesive drug delivery.
  • nasal cavity also provides a potential site for the development of formulations where bioadhesive polymers can play an important role.
  • the nasal mucosal layer has a surface area of around 150-200 cm 2 .
  • the nasal cavity is lined with mucous membrane containing columnar cells, goblet cells, and basal cells. Both, keratinized and nonkeratinized epithelial cells are present depending upon location within nasal cavity.
  • the residence time of a particulate matter in the nasal mucosa varies between 15 and 30 min, which has been attributed to the increased activity of the mucociliary layer in the presence of foreign particulate matter.
  • Gastrointestinal tract is also a potential site for the development of bioadhesive based formulations.
  • the various bioadhesive polymers which have been used for the development of oral delivery systems include chitosan, poly(acrylic acid), alginate, poly(methacrylic acid) and sodium carboxymethyl cellulose (Asane et al, 2007).
  • the skilled person is aware of the anatomical differences of the mucus membrane at varying body locations and, therefore, he would consider the different requirements needed for developing bioadhesive drug delivery systems to be used at specific body locations, e.g., the mucosa of the stomach.
  • the present invention relates to the composition comprising a carrier.
  • a carrier refers to the components and thus the property of the controlled release drug delivery system, particularly a gastroretentive drug delivery system.
  • the carrier of the present invention mediates the locally and timely controlled release of the one or more glucocorticoid(s) of the present invention.
  • the carrier comprises a pharmaceutically acceptable carrier comprising a chemical composition, compound, or solvent with which an active ingredient may be combined and which, following the combination, can be used to administer the active ingredient to a subject.
  • pharmaceutically acceptable carrier includes, but is not limited to, one or more of the following: excipients; surface active agents; dispersing agents; inert diluents; granulating and disintegrating agents; binding agents; lubricating agents; preservatives; physiologically degradable compositions such as gelatin; aqueous vehicles and solvents; oily vehicles and solvents; suspending agents; dispersing or wetting agents; emulsifying agents, demulcents; buffers; salts; thickening agents; fillers; antioxidants; stabilizing agents; and pharmaceutically acceptable polymeric or hydrophobic materials and other ingredients known in the art.
  • compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.
  • pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for ethical administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts.
  • compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation.
  • Subjects to which administration of the pharmaceutical compositions of the invention is contemplated include, but are not limited to, humans and other primates, and other mammals. Preferably, subjects are humans.
  • Various types of formulations are available such as tablets, syrups, suspensions, suppositories, injections, transdermal and patches having different types of drug delivery mechanisms.
  • formulation or“drug formulation” or’’dosage form” as used herein refers to the applied form of a composition containing at least one therapeutic agent or medication, wherein the dosage form may be in the form of a gel, lozenge, pill, tablet, effervescent tablet, capsule, membrane, strip, liquid, patch, film, spray, oral suspension or other form.
  • dosage forms which are suitable to be applied for the composition of the present invention.
  • the drug should be delivered to its site of action at such rate and concentration to achieve maximum therapeutic effect and minimum adverse effect.
  • the drug formulation of the present invention can be any formulation as long as it is compatible with the topical administration of said drug, i.e.
  • composition comprising the one or more glucocorticoid(s), in accordance with the present invention.
  • the composition comprising the one or more glucocorticoid(s) formulated as a topical composition is delivered to the stomach, preferably the fimdus and the corpus of the stomach.
  • a formulation may comprise additional, non-active components, such as pharmaceutical excipients, fillers, carrier materials etc. that may be used to modify or improve the drug release, improve its physical and/or chemical stability, dosage form performance, processing, manufacturing, etc.
  • the present invention relates to the composition comprising a carrier for oral administration.
  • a carrier for oral administration refers to a suitable vehicle, which can be used to form and apply the present compositions to the oral cavity in a safe and effective manner.
  • vehicle may include materials such as sodium benzoate, potassium sorbate, ethylenediamine acetic disodium, citric acid, sucrose, methylcellulose, (cassis) flavor, water, other suitable materials, and mixtures thereof.
  • Liquid oral dosage forms are easy to administer as compared to unit solid dosage forms but sustained effect are not achieved due to less residential time in gastrointestinal tract so, due to this problem suitable oral preparations are used to overcome the problems.
  • Suitable oral preparations may be prepared with aqueous-based solutions such as sodium bicarbonate (e.g., Brioschi®), or in gels and suspensions for topical oral administration.
  • a gel dosage form comprises a liquid before administration and after it converts into gel by various mechanisms in gastric environment so that a sustained release can be achieved.
  • the oral preparations are particularly well-suited for disorders and inflammatory responses involving the mucosa of the stomach.
  • Oral formulations of steroids typically are used to treat inflammation and pain associated with chronic conditions such as rheumatoid arthritis and lupus.
  • the orally administered drug delivery has proven particularly useful and offers several advantages over other drug delivery systems including bypassing hepatic first-pass metabolism, increasing the bioavailability of drugs, improved patient compliance, excellent accessibility, unidirectional drug flux, and improved barrier permeability compared, for example, to intact skin.
  • Oral delivery is currently the gold standard in the pharmaceutical industry where it is regarded as the safest, most convenient and most economical method of drug delivery having the highest patient compliance. Also, solid oral delivery systems do not require sterile conditions and are, therefore, less expensive to manufacture (Nagar et al., 2011).
  • the carrier of the present invention is in the form of an effervescent tablet, an oral suspension or a gel.
  • the carrier of the present invention is in the form of an effervescent tablet.
  • the term“effervescent” refers to those agents which evolve gas, and the bubble or gas generating the action is most often the result of the reaction of a soluble acid source and an alkali metal carbonate or carbonate source. The reaction of these two general classes of compounds produces carbon dioxide gas upon contact with water included in saliva.
  • the term“effervescence” refers to the reaction of acids and bases producing carbon dioxide. Examples of acids used in this reaction are citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, acid citrates, succinic acid and mixtures thereof. Citric acid is the most commonly used, and it imparts a citrus-like taste to the product.
  • bases used in the effervescent reaction are sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium carbonate, sodium glycocarbonate, carboxylysine and mixtures thereof
  • Sodium bicarbonate is very common in effervescent formulas.
  • Carbonate sources include dry solid carbonate and bicarbonate salts such as sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium carbonate and sodium sesequicarbonate, sodium glycine carbonate, L-lysine carbonate, arginine carbonate and amorphous calcium carbonate.
  • Other source of effervescence can be included and the present invention is not limited to those specifically set forth herein.
  • the effervescent tablet may be coated with a thin layer of a rapidly dissolving water soluble polymer or pharmaceutical excipient. A coating of a water soluble excipient results in faster hydration and gas formation than a coating of water soluble polymer.
  • the carrier may be in the form of an effervescent tablet, in particular in the form of a coated effervescent tablet.
  • a coated effervescent tablet may comprise a core and a coat.
  • a coated effervescent tablet may comprise a core, the core comprising a powder and/or the active agent(s), such as one or more glucocorticoid(s), and an effervescent agent, and a coat.
  • the coat can isolate the core from the environment, thereby protecting the core from oxidation and avoiding parenteral decomposition.
  • the composition comprising one or more glucocorticoid(s) can be formulated as an effervescent tablet.
  • the tablet as used herein may be a tablet that is not orodispersible.
  • the passage takes variably long in different people, depending on anatomical and physiological factors.
  • the constituents of the tablet start to dissolve in the saliva.
  • Drinking is recommended after swallowing the composition of the present invention in order to minimize dissolving of the tablet in the mouth and oesophagus and to maximize dissolving of the tablet in the stomach, preferably the fundus and the corpus of the stomach.
  • it may be recommended to drink at least 50-100 ml of liquid, preferably water, in order to minimize dissolving of the tablet in the mouth and oesophagus and to maximize dissolving of the tablet in the stomach, preferably the fundus and the corpus of the stomach.
  • the ingredients are evenly distributed in the solution, so that high, localized concentrations cannot occur. This effect may be additionally be supported, e.g. if the patient rests in a lateral position after administration of the composition.
  • effervescent tablets have the potential to be used for controlled release drug delivery, but coupling of mucoadhesive properties to tablet may have additional advantages, for example, it offers efficient absorption and enhanced bioavailability of the drugs due to a high surface to volume ratio and may facilitate a much more intimate contact with the mucus layer. Further desirable characteristics of the dosage form of an effervescent tablet may include allowance of high drug loading, no requirement of specific packaging, cost effectiveness as minimum number of ingredients are required and good chemical stability as conventional oral solid dosage.
  • effervescent tablets There are several methods for the preparation of effervescent tablets known in the art including but not limited to addition of disintegrants, molding, compaction, spray-drying, freeze-drying or lipophilization, mass extrusion and some special methods are melt granulation, phase transition, and sublimation (Dey et al, 2010; Dobetti 2001; Yang et al, 2004; Ozeki et al, 2003; Radke et al, 2009; Swamy et al, 2008; Abderbary et al, 2004; Kuno et al, 2005; Koizumi et al, 1997; Swamy et al, 2009; Kaushik et al, 2004; Mohire et al, 2009; Chang et al, 2000; Lindgren et al, 1993; Bandari et al 2008; US 6.207.199 (2001); US 6.807.576 (1998); US 6.197.348 (2001).
  • Important ingredients that may be used in the formulation of effervescent tablets include
  • disintegrants as exipients increase the rate of disintegration and hence the dissolution.
  • examples for disintegrants include crospovidone, microcrystalline cellulose, sodium starch glycolate, sodium carboxy methyl cellulose, pregelatinzed starch, carboxy methyl cellulose, and modified com starch.
  • Tablets formed by molding process include moistening, dissolving, or dispersing the drugs with a solvent then molding the moist mixture into tablets by applying lower pressure in compression molding, but always lower than the conventional tablet compression.
  • the powder mixture may be sieved prior to the preparation.
  • the preparation by compression is carried out by addition of super disintegrants.
  • effervescent tablets are made up of hydrolyzed or unhydrolyzed gelatin as supporting agent for matrix, mannitol as bulk agent, and sodium starch glycolate or croscarmellose sodium as disintegrating agent. Sometimes in order to improve the disintegration and dissolution, citric acid and sodium bicarbonate are used. Finally, the formulation is spray-dried in a spray drier.
  • the drug may be dissolved or dispersed in an aqueous solution of a carrier.
  • the mixture may be poured into the wells of the preformed blister packs.
  • the trays holding the blister packs are passed through liquid nitrogen freezing tunnel to freeze the drug solution.
  • the frozen blister packs are placed in refrigerated cabinets to continue the freeze drying. Finally, the blisters are packaged and shipped.
  • Mass extrusion involves softening the active blend using the solvent mixture of water soluble polyethylene glycol, methanol and expulsion of softened mass through the extruder or syringe to get a cylindrical shape of the product into even segments using heated blade to form tablets.
  • Resulting tablet dosage forms vary on several parameters like mechanical strength, porosity, dose, stability, taste, mouth feel, dissolution rate and overall bioavailability.
  • drugs categorized into classes can be incorporated in effervescent tablets including the classes but not limited to analgesics and anti-inflammatory agents, antiepileptics, antifungal agents, antimalarial, antigout agents, antihypertensive agents, antibacterial agents, antineoplastic agents, diuretics, antiparkinsonism agents, anxiolytic, sedatives, hypnotics, and neuroleptics, lipid regulating agents, opoid analgesics, corticosteroids, oral vaccines local anaesthetics and nutritional agents.
  • the glucocorticoids of the present invention may be incorporated in effervescent tablets by using the methods known in the art as outlined but not limited to the methods described above. Moreover, the skilled person knows how to select suitable parameters for pharmaceutical formulation in order to prepare an effervescent tablet.
  • pharmaceutical formulation refers to preparations which are in such form as to permit the active ingredients to be effective, and which contains no additional components which are toxic to the subjects to which the formulation would be administered.
  • the carrier of the present invention may be in the form of an oral suspension.
  • oral suspension refers to a liquid dosage form wherein the drug is solubilised or suspended into suitable aqueous vehicles and wherein the oral suspension refers to a gastroretentive extended release suspension composition which may be in the form of a suspension or a reconstituted powder for suspension.
  • the powder for suspension may comprise coated cores of active ingredient or a mixture of coated cores of active ingredient, one or more osmogents, one or more gel forming agents and/or one or more gas generating agents, and pharmaceutically acceptable excipients.
  • This powder for suspension may be reconstituted with a pharmaceutically acceptable vehicle or a suspension base to form a gastroretentive extended release suspension composition.
  • suspension base refers to a medium which is used to suspend the coated cores of the active ingredient or to reconstitute the extended release powder for suspension of the active ingredient.
  • the suspension base comprises a pharmaceutically acceptable vehicle, one or more osmogents, and pharmaceutically acceptable excipients.
  • the prior art discloses various approaches for the preparation of extended release liquid compositions.
  • U.S. Patent No. 6,156,340 discloses a controlled release suspension comprising inert cores coated with an active ingredient, which were further coated with two layers of polymers having increasing permeability for water.
  • 7,906, 145 discloses a sustained release suspension of microcapsules in an aqueous liquid phase, wherein each microcapsule comprises a core of an active ingredient and a film coating applied to the core which controls the modified release of the active ingredient in gastrointestinal fluids, comprising a film-forming polymer, a nitrogen-containing polymer, a plasticizer, and a surfactant/lubricant.
  • PCT Publication No. WO 2011/107855 discloses a ready to use sustained release oral suspension comprising inert pellets surrounded by a seal coating, an active ingredient layer surrounding the seal coated inert pellets, and a coating layer comprising a rate- controlling polymer surrounding the active ingredient layer.
  • WO 2011/077451 discloses a controlled release suspension comprising an active ingredient loaded core and a polymer dispersion comprising a controlled-release polymer, wherein said suspension has a duration of therapeutic effect for at least about 6 hours to about 30 hours after oral administration.
  • PCT Publication No. WO 2008/122993 discloses a suspension of an active ingredient containing microparticles with at least one coat of a pH-independent polymer.
  • PCT Publication No. WO 2012/063257 and U.S. Publication No. 2008/0118570 disclose controlled release suspensions employing ion-exchange resins.
  • the carrier of the composition comprising one or more glucocorticoid(s) is in the form of a gel.
  • gels are typically used where a solid form would affect the patient’s comfort.
  • Certain mucoadhesive polymers comprising the gel for example, sodium carboxymethylcellulose, carbopol, hyaluronic acid, pectins, xyloglucan, gellan gum, sodium alginate and xanthan gum, undergo a phase change from liquid to semisolid.
  • the polymer(s) is preferably a water soluble salt of one or more polyuronic acids. The gel forming polymer cross-links with time to form a stable structure.
  • the gel forming polymer results in a hycdrodynamically balanced system providing a tortuous diffusion pathway for the drug, thereby resulting in a timely and locally controlled drug release of the glucocorticoid(s) and whereby the matrix is retained in the stomach for an extended period of time.
  • the pharmaceutical composition may also contain other conventional pharmaceutical excipients, for example, water soluble diluents such as lactose, dextrose, mannitol, sorbitol, and the like; water insoluble diluents such as starch, microcrystalline cellulose, powdered cellulose, and the like; or lubricants such as talc, stearic acid or its salt, magnesium stearate, and the like.
  • water soluble diluents such as lactose, dextrose, mannitol, sorbitol, and the like
  • water insoluble diluents such as starch, microcrystalline cellulose, powdered cellulose, and the like
  • lubricants such as talc, stearic acid or its salt, magnesium stearate, and the like.
  • Gel formulation based on swelling may comprise ph dependent gelling and/or temperature dependent gelling.
  • Temperature dependent gelling refers to liquid aqueous solutions before administration, but gel at body temperature. These hydrogels are liquid at room temperature (20°C -25°C) and undergo gelation when in contact with body fluids (35°C -37°C), due to an increase in temperature. This approach exploits temperature-induced phase transition. Some polymers undergo abrupt changes in solubility in response to increase in environmental temperature (lower critical solution temperature, LCST).
  • polymers examples include but are not limited to Pluronics ( poly (ethylene oxide)-poly(propylene oxide)-poly (ethylene oxide)(PEO-PPOPEO) Triblock), polymer networks of poly(acrylic acid) (PAA) and polyacrylamide (PAArn) or poly(acrylamide-co-butyl methacrylate).
  • Pluronics poly (ethylene oxide)-poly(propylene oxide)-poly (ethylene oxide)(PEO-PPOPEO) Triblock
  • PAA polyacrylic acid
  • PAArn polyacrylamide
  • PAAm polyacrylamide-co-butyl methacrylate
  • Such a polymer solution is a free flowing liquid at ambient temperature and gels at body temperature.
  • Polymer networks of poly (acrylic acid) (PAA) and polyacrylamide (PAAm) or poly (acryl amide-co- butyl methacrylate) have positive temperature dependence of swelling (Shah et al, 2012; Neha et al, 2013).
  • Ph dependent gelling (rbopol®, carbomer or its derivatives, polyvinylacetal diethylaminoacetate (AEA), mixtures of poly (methacrylic acid) (PMA) and poly (ethylene glycol) (PEG)) shows change from sol to gel with change of pH. Swelling of hydrogel increases as the external pH increases in the case of weakly acidic (anionic) groups, but decreases if polymer contains weakly basic (cationic) groups.
  • Gel formulation based on chemical stimulation and ionic crosslinking comprises certain ion sensitive polysaccharides such as carrageenan, Gellan gum(Gelrite®), pectin, sodium alginate undergoing phase transition in presence of various ions such as K + , Ca 2+ , Mg 2+ , Na + .
  • ion sensitive polysaccharides such as carrageenan, Gellan gum(Gelrite®), pectin, sodium alginate undergoing phase transition in presence of various ions such as K + , Ca 2+ , Mg 2+ , Na + .
  • valent cations e.g. Ca 2+ crosslinks alginate due to the interaction with guluronic acid (Guo et al, 1998).
  • Gel formulation based on chemical stimulation and enzymatic crosslinking comprises certain enzymes which operate efficiently under physiologic conditions without need for potentially harmful chemicals such as monomers and initiators providing a convenient mechanism for controlling the rate of gel formation, which allows the mixtures to be injected before gel formation in situ (Podual et al., 2000).
  • Gel formulation based on physical mechanisms comprise swelling of polymer by absorption of water causing formation of a gel.
  • Certain biodegradable lipid substances such as myverol (glycerol mono-oleate) form gels under such phenomenon (Esposito and Carratto, 1996; Geraghaty and Attwood, 1997; Vintage and Gailloud, 2000).
  • the carrier of the composition is a controlled release carrier suitable to release an effective amount of one or more glucocorticoid(s) at the topical area at a time period between 0 and 15 minutes after onset of topical treatment with the composition.
  • the controlled release e.g. in a timely and/or locally manner, may be additionally supported, e.g. if the patient rests in a lateral position after administration of the composition, as outlined above.
  • controlled release refers to a drug release profile designed to optimize delivery of the drug to a particular site(s) of absorption such as the stomach while still providing effective treatment over a predetermined extended period of time such as once or twice daily. Further, the term“controlled release” refers to the timely controlled delivery of an effective amount of the one or more glucocorticoid(s) to the topical area to be treated, e.g. the mucosa of the stomach of AIG patient, which is controlled by the dosage form of the carrier of the present invention.
  • Various controlled release methods and formulations are known the art and described above. Common methods of obtaining controlled release systems include but are not limited to polylactides (U.S. Pat. No.
  • polymeric capsules For example, it is known to fill polymeric capsules with a solid, liquid, suspension or gel containing a therapeutic agent which is slowly released by diffusion through the capsule walls.
  • Heterogeneous matrices for example compressed tablets, control the release of their therapeutic agents either by diffusion, erosion of the matrix or a combination of both.
  • Other controlled release systems focus on the fabrication of laminates of polymeric material and therapeutic agent which are then formed into a sandwich, relying on diffusion or erosion to control release of the therapeutic agent.
  • Liquid-Liquid encapsulated in a viscous syrup-like solution of polymer have also been known to be useful in controlling release of the therapeutic agent.
  • the controlled release system comprises the carrier of the present invention in the form of an effervescent tablet, an oral suspension or a gel.
  • the controlled release system comprises the carrier of the present invention in the form of a gel.
  • the composition comprising the one or more glucocorticoid(s) may comprise effervescent-coating formulations. Such effervescent-coated formulations are known in the art, e.g.
  • effervescent tablet formulation coated with hydro xypropyl methylcellulose phthalate as an enteric material, is suitable to disintegrate a composition in the upper part of the intestine.
  • CN 105663078 Another Example of an effervescent-coated formulation is disclosed in CN 105663078, which relates to a pharmaceutical preparation of colloidal tartaric bismuth tablets including various disintegrants such as effervescent agents, adhesives, anti-adhesive agents, enteric coating agents and coating agents disintegrated in the lower digestive tract.
  • this concept of an effervescent-coated formulation can be applied for different target areas, including the stomach, in order to increase the bioavailability of a composition at a specific area as disclosed, e.g., in US 3,91,335 Bl.
  • Coatings applied in thin films to tablets can be used for various reasons; they can for instance modify release of biologically active substances, clarify identification of products, and make tablets easier to swallow.
  • Coating materials are also used for protection of biological active substances from the environment e.g. air, moisture and light. Coating materials which function as moisture barriers and/or protects from oxidation can be found among both pharmaceutically acceptable materials and components used for the preparation of edible films for the food industry.
  • Edible film forming materials have been classified by Bourtoom (International Food Research Journal 15(3): 237- 248 (2008)) into three categories: hydrocolloids (such as proteins, polysaccharides, and alginate), lipids (such as fatty acids, acylglycerol, waxes) and composites (mixtures of the other two classes).
  • hydrocolloids such as proteins, polysaccharides, and alginate
  • lipids such as fatty acids, acylglycerol, waxes
  • composites mixture of the other two classes.
  • One reason to coat tablets is to provide a barrier against moisture and oxygen.
  • Shellac and zein films are examples of coatings that are used in food applications. Zein is the water-insoluble prolamine from com gluten. It is unique in its ability to form odorless, tasteless, clear, hard and almost invisible edible films. Since Zein films are completely safe to ingest, it is the perfect coating for foods and pharmaceutical ingredients.
  • Zein films provide an excellent gas barrier against oxygen at low water contents.
  • Modified cellulose such as methyl mellulose (MC), hydroxyl propyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC) and carboxymethyl cellulose CMC possess good film forming characteristic; films are generally odorless and tasteless, flexible and moderate protection to moisture and oxygen transmission. Film forming chitosans are clear, tough, flexible and have good oxygen barrier properties. Films produced from high amylose com starch has also been reported to be good oxygen barrier properties. Synthetic polymers may also be used. Polyvinyl alcohol is odorless tasteless and used as a barrier film for food supplement tablets.
  • BASF has under the trade name Kollicoat, developed a polyvinyl alcohol-polyethylene glycol graft copolymer for instant release coating for tablets which exhibits reliable protection properties for active ingredients against light, oxygen and moisture.
  • Kollicoat developed a polyvinyl alcohol-polyethylene glycol graft copolymer for instant release coating for tablets which exhibits reliable protection properties for active ingredients against light, oxygen and moisture.
  • Such coatings are known in the art and, for example, disclosed in US20130108745 Al.
  • the composition of the one or more glucocorticoid(s) may comprise an effervescent-coated formulation of the composition comprising the one or more glucocorticoid(s).
  • said effervescent-coated formulation comprising one or more effervescent and a coating agent(s)
  • the topical area to be treated comprises or is the mucosa of the stomach.
  • the topical area to be treated comprises or is the mucosa of the fundus and/or the corpus of the stomach.
  • the effervescent-coated formulation of the composition comprising the one or more glucocorticoid(s) may use the effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability.
  • Such an enhancement in bioavailability may be, e.g., due to the following mechanisms: reducing the thickness and/or the viscosity of the mucus layer; alteration of the tight junctions between cells, thus promoting absorption through the paracellular route and/or inducing a change in the cell membrane structure, thus promoting transcellular absorption.
  • the composition of the one or more glucocorticoid(s) may include an amount of effervescent agent effective to aid penetration and to promote absorption of the composition in the topical area to be treated.
  • Effervescent agents of the present invention include but are not limited to dry solid carbonate and bicarbonate salt such as, preferably, sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium carbonate and the like.
  • the coating agent of the effervescent-coated formulation of the composition comprising the one or more glucocorticoid(s) may aid in releasing the drug in a specific area, i.e. the topical area to be treated as provided by the present invention.
  • This site-specific delivery may be promoted by various mechanisms, for example, but not limited to metabolizing the coating agents by enzymes present in a specific part of the area to be treated, thus releasing the drug in that area, e.g. as described in US 6,931,335.
  • the coating agents may be used to prevent the release of the one or more glucocorticoid(s) from the composition before the composition reaches the topical area to be treated.
  • the coating may be used in conjunction with an effervescence to cause the effervescence to occur at the topical area to be treated.
  • coating agents used in the present invention include but are not limited to cellulose derivatives including cellulose acetate phthalate (CAP); shellac and certain materials sold under the trademark EudragitTM (various grades may be used in specific combinations) and hydroxypropylmethyl cellulose phthallate.
  • the coating agent used in the present invention may comprise hydroxypropylmethyl cellulose phthallate.
  • the one or more glucocorticoid(s) is/ are locally effective at the topical area to be treated.
  • the glucocorticoids may not be transported past the “absorption window” prior to releasing essentially all the drug so that maximum bioavailability may be attained.
  • Targeting the drug to the pathological tissue may be usually preferable for treatment of localized disorders, as the concentration of the drug attained in the diseased tissue or organ may be higher than its systemic concentration, resulting in enhanced effectiveness of the drug in the target organ or tissue, with reduced systemic side effects.
  • the topical area to be treated comprises or is the mucosa of the stomach. More preferably, the topical area to be treated comprises or is the mucosa of the fundus and/or the corpus of the stomach.
  • AIG in a patient is determined histologically, by the occurrence of gastric inflammation, by the occurrence of destruction of parietal cells, and by a subsequent failure in production of gastric acids, resulting in higher gastrin secretion, and/or increased parietal cell antibody (PCA)and/or anti-intrinsic factor antibody (IFA) levels in a sample of the patient, wherein an increase in PCA or IFA levels and/or a pH increase of gastric juice, compared to a control level is indicative for the patient of having autoimmune gastritis.
  • PCA parietal cell antibody
  • IFA anti-intrinsic factor antibody
  • AIG may be determined by inflammatory markers since AIG is characterized by a gastric inflammation of the corpus and the fundus, sustained by a cell-mediated aggression by CD4+CD25- Thl lymphocyte effectors.
  • the main target of immunological injury is the H+/K+-adenosine-triphosphate enzyme (ATPase), a protein of the membrane that coats the secretory canaliculi of the parietal cells and is responsible for the secretion of the hydrogen ions in exchange for the potassium ions (proton pump).
  • ATPase H+/K+-adenosine-triphosphate enzyme
  • the CD4+CD25- T-cells Induced by a triggering factor not yet entirely identified, the CD4+CD25- T-cells, together with macrophages and B lymphocytes, infiltrate the submucosa, the lamina intestinal, and the gastric glands causing the loss of parietal or P/Dl cells.
  • the damage of the corpus and fundus mucosa results in hypo/achlorhydria including failure in production of gastric acids, as a result of destruction of the parietal cells; hypergastrinemia, i.e.
  • AIG AIG may be made by combined findings of anemia, serological (blood) studies, endoscopic findings, and gastric biopsy diagnosis.
  • Abnormal serological findings include but are not limited to increased serum gastrin, reduced pepsinogen I, anti-parietal cell antibodies, anti- intrinsic factor antibodies, low serum iron, and low vitamin B I2 .
  • the natural folds in the proximal stomach may appear flattened (‘atrophic’), while the distal or antral part of the stomach appears normal or unaffected. Occasionally, small nodules may be seen in the proximal stomach; which may show carcinoid tumor on biopsy.
  • Biopsies taken from the proximal stomach may show depleted or lost parietal or oxyntic cells (atrophy), increased chronic inflammatory cells (chronic gastritis), intestinal metaplasia, and increased small clusters or hyperplasia of neuroendocrine cells (so-called ECL cells).
  • the diagnosis of gastritis should be based on the separate assessment of at least three samples from the antrum (including the incisura angularis), and two from the gastric body; and any focal lesions should be biopsied too. When such topographically well-defined samples are available, the presence of chronic gastritis with minimal or no active inflammation in the corpus, and a relatively normal antral mucosa in the absence of H.
  • active AIG in a patient is determined by the PC A level in a sample of the patient, wherein a PC A level above 100 U/ml compared to a control level is indicative for the patient of having active autoimmune gastritis.
  • a frequent clinical presentation of AIG is pernicious anemia (PA), a megaloblastic anemia arising from vitamin B I2 malabsorption as a consequence of intrinsic factor deficiency or the iron deficiency anemia due to iron malabsorption as a consequence of reduced gastric acid secretion.
  • PA pernicious anemia
  • Treatment of autoimmune gastritis concerns two separate aspects: Treatment for anemia and early detection of carcinoma and carcinoid in the stomach.
  • Treatment for anemia include substitution for iron and/or vitamin B I2 .
  • Early detection of carcinoma and carcinoid in the stomach involves endoscopic surveillance of gastric mucosa, optimal biopsy tissue procurement, evaluation and removal of the carcinoid nodules.
  • treatment of patients having autoimmune gastritis implies that AIG has been diagnosed in a patient/subject.
  • a patient/subject suspected of suffering from AIG may show specific clinical and/or pathological symptoms which a skilled person can attribute to the specific pathological condition occurring in AIG (i.e., diagnose).
  • a response to treatment of autoimmune gastritis in a patient is indicated by histological remission, by reduction of gastric inflammation, by suppression of the destruction of parietal cells, by the pH level of gastric juice, specifically serum gastrin, and/or by the PCA and IFA levels, wherein a decrease in PCA/IFA level and/or a decrease of gastric juice pH, specifically reduction in gastrin, compared to a predetermined level or a control is indicative for a response to said treatment.
  • a response to treatment of autoimmune gastritis in a patient is indicated by reduction of the gastric pH level of gastric juice, preferably reduction of the pH level by more than 2.
  • the “treatment” of AIG may, for example, lead to a halt in the progression (e.g., no deterioration of symptoms) or a delay in the progression (in case the halt in progression is of a transient nature only).
  • The“treatment” may also lead to a partial response (e.g., amelioration of symptoms) or complete response (e.g., disappearance of symptoms) of the subject/patient suffering from AIG.
  • the“treatment” of AIG may also refer to an amelioration, which may, e.g., lead to a halt in the progression or a delay in the progression. Such a partial or complete response may be followed by a relapse.
  • a subject/patient may experience a broad range of responses to a treatment (e.g., the exemplary responses as described herein below).
  • the treatment of a disorder or disease may, inter alia, comprise curative treatment (preferably leading to a complete response and eventually to healing of the disorder or disease) and palliative treatment (including symptomatic relief).
  • curative treatment preferably leading to a complete response and eventually to healing of the disorder or disease
  • palliative treatment including symptomatic relief
  • the effect may also be prophylactic in terms of completely or partially preventing a disease/medical conditio n/disorder or symptom thereof and/or may be therapeutic in terms of partially or completely curing a disease/medical condition/disorder and/or adverse effect attributed to the disease/medical conditio n/disorder.
  • topical treatment refers to the application of a pharmaceutical composition at the site of inflammation, i.e., non-systemic administration.
  • topical refers to a localized area of the body or to the surface of a body part of the location of the effect.
  • a pharmaceutical composition pertains to a particular surface area.
  • the topical area of the composition comprising one or more glucocorticoid(s) used for the topical treatment of AIG comprises or is the mucosa of the stomach.
  • topical area of the composition comprising one or more glucocorticoid(s) used for the topical treatment of AIG is the mucosa of the stomach.
  • the topical area of the composition comprising one or more glucocorticoid(s) used for the topical treatment of AIG comprises the mucosa of the fundus and/or the corpus of of the stomach. In certain aspects, topical area of the composition comprising one or more glucocorticoid(s) used for the topical treatment of AIG is the mucosa of the fundus and/or the corpus of the stomach. As provided herein, the glucocorticoid(s) are formulated in a dosage form to be used as topical glucocorticoid(s).
  • topical glucocorticoid(s) may be commonly used to treat inflammatory skin conditions such as atopic eczema, rash and dermatitis.
  • Hydrocortisone and betamethasone are examples of low- and high-potency topical glucocorticoid(s).
  • the one or more glucocorticoid(s) is/ are locally effective at the topical area.
  • glucocorticoid(s) and the term“corticosteroid(s)” are used interchangeably and refer to any group of natural isolated or biologically active derivatives of the cortisol secreted from the adrenal cortex or synthetic steroid hormones.
  • Exemplary glucocorticoids include, without limitation, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, triamcinolone diacetate, triamcinolone hexacetonide, beclomethasone, dipropionate, beclomethasone dipropionate monohydrate, flumethasone pivalate, diflorasone diacetate, fluocinolone acetonide, fluorometholone, fluorometholone acetate, clobetasol propionate, desoximethasone, fluoxymesterone, fluprednisolone, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone cypionate, hydrocortisone probutate, hydrocortisone valerate, cortisone acetate, paramethasone acetate, methyl
  • the one or more glucocorticoid(s) of the present invention is/are selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, beclomethasone, dipropionate, dexamethasone sodium phosphate, fluticasone propionate, hydrocortisone, prednisone, prednisolone, mometasone, tipredane, and butixicort.
  • the glucocorticoid is budesonide.
  • Suitable pharmaceutically acceptable salts of glucocorticoids include, for example, the aceponate, acetate, butyrate, dipropionate, etabonate, furoate, propionate, and valerate salts thereof.
  • the compositions comprising one or more glucocorticoid(s) are selected from the group consisting of budesonide, flunisolide, triamcinolone acetonide, beclomethasone, dipropionate, dexamethasone sodium phosphate, fluticasone propionate, hydrocortisone, prednisone, prednisolone, mometasone, tipredane, and butixicort.
  • the glucocorticoid is budesonide.
  • Glucocorticoids which are not specifically disclosed herein but which are useful for the treatment of patients having AIG are expressly included and intended within the scope of the present invention.
  • glucocorticoids possess potent anti-inflammatory properties and may be used to treat a variety of inflammatory and autoimmune disorders. Conditions commonly treated with glucocorticoids include asthma; arthritis (eg, rheumatoid arthritis); autoimmune disorders such as lupus, and multiple sclerosis; skin conditions such as eczema and rashes; some types of cancer; and Addison’s disease (insufficient cortisol production) as well as the prevention of organ rejection in transplant recipients.
  • arthritis eg, rheumatoid arthritis
  • autoimmune disorders such as lupus, and multiple sclerosis
  • skin conditions such as eczema and rashes
  • Addison’s disease insufficient cortisol production
  • budesonide is a potent glucocorticoid with a high topical activity and low systemic availability in therapeutic doses.
  • Budesonide may be well absorbed from the intestine, have an extensive first pass metabolism and 80 to 90% of an orally given dose may be metabolized in the liver during the first liver pass in healthy subjects.
  • the systemic bioavailability may be about 10%.
  • budesonide may be sometimes used in inhaled form to treat inflammatory diseases or conditions such as asthma, or nasal inflammation, or in other forms, such as by oral delivery or enema, to treat other lower inflammatory lower gastrointestinal diseases or conditions such as Crohn's disease.
  • Flunisolide is a synthetic corticosteroid with anti-inflammatory and anti-allergic properties and is often prescribed as treatment for allergic rhinitis.
  • Triamcinolone acetonide the acetonide salt form of triamcinolone, is a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.
  • Beclomethasone dipropionate is the dipropionate ester of a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma.
  • Fluticasone propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, anti-inflammatory and antipruritic effects.
  • Hydrocortisone is the main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
  • Prednisone is a synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
  • Mometasone is a pregnadienediol derivative anti allergic agent and anti-inflammatory agent that is used in the management of asthma and allergic rhinitis. It is also used as a topical treatment for skin disorders.
  • Dexamethasone sodium phosphate is a sodium phosphate salt form of dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. Dexamethasone sodium phosphate may be used in the treatment of adrenocortical insufficiency.
  • the pharmaceutical composition may incorporate a high dose medicament.
  • the composition of the invention comprises a pharmaceutically effective amount of at least one active drug.
  • This amount is that determined by such considerations as are known in the art, and generally means an amount sufficient to prevent, alleviate, treat or cure a disease or disorder.
  • doses of individual steroids are classified as being low dose (7.5 mg/day or less), medium dose (between 7.5 and 30 mg/day), or high dose (greater than 30 mg/day).
  • Steroid doses often are described in terms of equivalent doses of prednisone (e.g., 5 mg of prednisone is equivalent to 4 mg of methylprednisolone) and also in terms of their duration of action, such as short, intermediate, or long acting.
  • An effective amount of the composition comprising one or more glucocorticoid(s) may be administered in a dose range of about 1 pg to about 20 mg, about 1 pg to about 10 mg, about 0.01 mg to about 10 mg, about 0.025 mg to about 10 mg, about 0.05 mg to about 5 mg, about 0.1 mg to about 5 mg, about 0.125 mg to about 5 mg, about 0.25 mg to about 5 mg, about 0.5 mg to about 5 mg, about 0.05 mg to about 2 mg, about 0.1 mg to about 2 mg, about 0.1 mg to about 1 mg, about 0.125 mg to about 2 mg, about 0.25 mg to about 2 mg, about 0.5 mg to about 2 mg, about 10 pg to about 2.5 mg, about 5 pg to about 500 pg, about 5 pg to about 250 pg, about 5 pg to about 130 pg, about 45 pg to about 1000 pg, about 1 pg, about 10 pg, about 16 pg, about 25 pg, about 27.5
  • the composition is administered in a dose of 0.01 mg/ml to 10 mg/ml budesonide, more preferably 0.05 mg/ml to 5.0 mg/ml budesonide, more preferably 0.1 to 1.0 mg/ml glucocorticoid, wherein the glucocorticoid is budesonide.
  • compositions may, inter alia, comprise an administration twice daily, every day, every other day, every third day, every fourth day, every fifth day, once a week, once every second week, once every third week, once every month, etc. If the composition is administered twice daily, then it may be preferred that the composition is administered at about twelve hour intervals. In certain aspects, the composition is administered at an interval of every three day, every two days, once a day, twice a day or three times a day. Preferably, the composition is administered at an interval of every two days, once a day, twice a day or three times a day, more preferably once a day, or twice a day.
  • an empty stomach of the patient enhances the release of the effective amount of one or more glucocorticoids at the topical area.
  • the gastric motility is not uniform, but passes through cycles termed migrating motor complexes (MMC). These MMC last about 2 h in total, but are divided into four phases, of which phase 3 results in the strongest contractions but lasts only about 15 min.
  • MMC migrating motor complexes
  • phase 3 results in the strongest contractions but lasts only about 15 min.
  • Non nutrient liquids are moved quickly from the stomach throughout the MMC, but solids of particle size 2 mm-e.g. partly dissolved drug are only moved into the intestine during the brief phase 3.
  • gastric emptying rate is an important determinant of oral drug bioavailability and gastrointestinal drug absorption. In this context, most drugs may be best absorbed on an empty stomach.
  • Some common examples include flucloxacillin, phenoxymethylpenicillin or oxytetraxcy cline.
  • the stomach is not empty, the food could delay the absorption of the drug. Take on an empty stomach means to take the drug within 1 hour before eating or 2 hours after eating. It is recommended and a preferred embodiment of the present invention to treat diseases related to the stomach at an empty stomach stage (e.g., omeprazole [Prilosec®], lanszoprazole [Prevacid®], pantoprazole [Protonix®], or esomeprazole [Nexium®, Vimovo®]).
  • omeprazole e.g., omeprazole [Prilosec®], lanszoprazole [Prevacid®], pantoprazole [Protonix®], or esomeprazole [Nexium®, Vimovo®].
  • an empty stomach may be particularly advantageous in the topical treatment of AIG by the composition of the present invention since the glucocorticoid can be delivered to the mucosa of the topical area to be treated without hindrance by food or drugs ingested by the patient.
  • the composition of the present invention which is locally effective may be efficiently delivered to the topical area to be treated in a patient with an empty stomach.
  • Drug-food interactions may also change the bioavailability of a drug.
  • the glucocorticoid(s) of the present invention may have an increased bioavailability when administered on an empty stomach.
  • a delayed stomach emptying of the patient extends the time period of the release of the effective amount of one or more glucocorticoids at the topical area in the patient.
  • the retention of dosage forms according to the present invention may be increased due to the delayed stomach emptying in AIG patients so that additional administration of medications delaying stomach emptying may not be necessary.
  • oral administration of a liquid to the patient may be suitable to control the time period in which the effective amount of one or more glucocorticoids at the topical area is released.
  • AIG autoimmune metaplastic atrophic gastritis
  • gastric carcinoid tumors including gastric neuroendocrine tumors
  • the most important risk factors besides amenia include severity of atrophy, the presence of intestinal metaplasia, the duration of the disease, and age over 50 years.
  • the incidence of gastric cancer development ranges from 1 to3 % for gastric carcinoma and from 2 to 12.5 % for carcinoid tumors in patients with AIG with or without pernicious anemia.
  • composition for use according to the present invention may further comprise reducing the risk of developing one or more diseases associated with autoimmune gastritis, specifically pernicious anemia (PA), more specifically autoimmune metaplastic atrophic gastritis (AMAG), gastric cancer or gastric neuroendocrine tumors.
  • autoimmune gastritis specifically pernicious anemia (PA), more specifically autoimmune metaplastic atrophic gastritis (AMAG), gastric cancer or gastric neuroendocrine tumors.
  • PA pernicious anemia
  • AMAG autoimmune metaplastic atrophic gastritis
  • the assessment of the extend and location of atrophy can be achieved by the operative link for gastritis assessment (OLGA) staging system for reporting gastritis in terms of stage (the OLGA staging system).
  • Gastritis staging arranges the histological phenotypes of gastritis along a scale of progressively increasing gastric cancer risk, from the lowest (stage 0) to the highest (stage IV).
  • stage 0 the lowest (stage 0) to the highest (stage IV).
  • the term "about” preferably refers to ⁇ 10% of the indicated numerical value, more preferably to ⁇ 5% of the indicated numerical value, and in particular to the exact numerical value indicated.
  • the primary objective of this study is to test whether a viscous suspension of oral budesonide reduces destruction of parietal cells in patients with AIG as detected by pH measurement of gastric juice.
  • Descriptive objectives of this study are to investigate whether low budesonide (2mg/day) concentrations are equally effective as 4mg/day), the effect of budesonide by patient’s age (below and above 40 years), and to investigate if budesonide effects differs in the subset of patients with a history of H. pylori infection.
  • a single center, randomized, 3-arm, double-blind, phase II clinical study is performed with lOml BVS (0.4mg/ml), lOml BVS (0.2mg/ml) or lOml placebo in AIG patients for 8 weeks.
  • the first visit of the first patient is at Q2, 2019, the first visit o the last patient is at Q3, 2019 and the last visit of the last patient is at Ql, 2020.
  • 100 patients are assessed for eligibility.
  • 60 patients are randomized into 3 groups with 20 patients per group (TBD with statistician, placebo response is expected ⁇ 5%, BVS >50%, i.e. those below 40 years of age). Randomization ratio is 1 :1 :1.
  • Inclusion criteria for the study are:
  • Renal insufficiency (GFR ⁇ 30ml/min/l 73m 2 );
  • liver disease or liver failure Severe liver disease or liver failure (elevation of liver enzymes above 3xULN);
  • Contaminant medications which are not allowed are:
  • acetylsalicylic acid more than 3 doses during the treatment period
  • Patients with AIG are identified from a large cohort (Loha for Life) and invited to participate in the study by telephone or email. After informed consent is obtained, medical history and vital signs, concomitant medication, physical examination, body weight and height are assessed together with a pregnancy test. A diary regarding upper GI symptoms is given to the patient. 1 to 3 weeks later the diary is collected, blood (PC A, IF A, Gastrin, CBC, chemistry, TSH, Vitamin B I2 , Ferritin, Transferrin Saturation, pregnancy test) and stool (H. pylori antigen) is sampled, and an upper GI endoscopy with a white light high resolution gastroscope such as Olympus 180 or higher is performed.
  • a white light high resolution gastroscope such as Olympus 180 or higher is performed.
  • Primary endpoint is the number of patients with a reduction of average gastric pH as measured by flushing juice pH and capsule pH of >2 (expected placebo response ⁇ 5%).
  • Histological changes Reduction in gastrin levels and antibody concentrations during and after treatment compared to the mean of the two pretreatment measurements.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions comprenant un ou plusieurs glucocorticoïdes utilisés dans le traitement topique de la gastrite auto-immune en administrant une quantité efficace du(des) glucocorticoïde(s) à la zone topique à traiter à l'aide d'un système d'administration de médicament à rétention gastrique qui libère le ou les glucocorticoïdes de manière opportune et locale. En particulier, la zone topique à traiter comprend ou est la muqueuse gastrique, de préférence le corpus et/ou le fundus de l'estomac et le glucocorticoïde préféré est le budésonide.
PCT/EP2019/068718 2018-07-11 2019-07-11 Glucocorticoïdes pour le traitement topique de la gastrite auto-immune WO2020011938A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18182910 2018-07-11
EP18182910.2 2018-07-11

Publications (1)

Publication Number Publication Date
WO2020011938A1 true WO2020011938A1 (fr) 2020-01-16

Family

ID=62916542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/068718 WO2020011938A1 (fr) 2018-07-11 2019-07-11 Glucocorticoïdes pour le traitement topique de la gastrite auto-immune

Country Status (1)

Country Link
WO (1) WO2020011938A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (fr) 1981-02-16 1982-08-25 Zeneca Limited Compositions pharmaceutiques pour la libération continue de la substance active
EP0133988A2 (fr) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Préparations pharmaceutiques contenant des peptides régulateurs à libération retardée et procédé pour leur préparation
US5360793A (en) 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
US6156340A (en) 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
US6197348B1 (en) 1996-05-07 2001-03-06 F H Faulding & Co., Limited Taste masked liquid suspensions
US6207199B1 (en) 1994-01-27 2001-03-27 The Board Of Regents Of The University Of Oklahoma Process for making a particulate support matrix for making a rapidly dissolving dosage form
US20020119941A1 (en) 2001-02-28 2002-08-29 Yawei Ni In-situ gel formation of pectin
US20040180088A1 (en) 2001-07-04 2004-09-16 Dudhara Kamlesh Mohanlal Gastric retention controlled drug delivery system
US6807576B1 (en) 2000-09-08 2004-10-19 International Business Machines Corporation Method and system for determining and graphically representing frame classification rule relationships
US20050063980A1 (en) 2001-10-30 2005-03-24 Gillian Eccleston Gastric raft composition
US6931335B2 (en) 2002-04-05 2005-08-16 Agilent Technologies, Inc. Jitter histogram approximation
US20080118570A1 (en) 2006-11-20 2008-05-22 Zhi Liu Polymer coated drug-ion exchange resins and methods
WO2008122993A1 (fr) 2007-04-09 2008-10-16 Panacea Biotec Limited Formulation de microparticules enrobées à libération contrôlée
WO2009064417A2 (fr) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions pour le traitement d'une inflammation gastro-intestinale
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US20110082221A1 (en) 2008-06-12 2011-04-07 Claire Haug In situ gelling systems as sustained delivery for front of eye
WO2011077451A2 (fr) 2009-12-22 2011-06-30 Abbott Healthcare Private Limited Composition pharmaceutique à libération contrôlée
WO2011107855A2 (fr) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale
US20120009275A1 (en) 2010-06-29 2012-01-12 Asfaw Bruktawit T In-situ forming hydrogel wound dressings containing antimicrobial agents
WO2012063257A2 (fr) 2010-11-10 2012-05-18 Rubicon Research Private Limited Composition à libération prolongée
US20130108745A1 (en) 2010-07-01 2013-05-02 Delante Health As Coated effervescent tablet
CN105663078A (zh) 2016-02-01 2016-06-15 中南大学 一种泡腾片的制备方法

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (fr) 1981-02-16 1982-08-25 Zeneca Limited Compositions pharmaceutiques pour la libération continue de la substance active
EP0133988A2 (fr) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Préparations pharmaceutiques contenant des peptides régulateurs à libération retardée et procédé pour leur préparation
US5360793A (en) 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
US6207199B1 (en) 1994-01-27 2001-03-27 The Board Of Regents Of The University Of Oklahoma Process for making a particulate support matrix for making a rapidly dissolving dosage form
US6156340A (en) 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
US6197348B1 (en) 1996-05-07 2001-03-06 F H Faulding & Co., Limited Taste masked liquid suspensions
US6807576B1 (en) 2000-09-08 2004-10-19 International Business Machines Corporation Method and system for determining and graphically representing frame classification rule relationships
US20020119941A1 (en) 2001-02-28 2002-08-29 Yawei Ni In-situ gel formation of pectin
US20040180088A1 (en) 2001-07-04 2004-09-16 Dudhara Kamlesh Mohanlal Gastric retention controlled drug delivery system
US20050063980A1 (en) 2001-10-30 2005-03-24 Gillian Eccleston Gastric raft composition
US6931335B2 (en) 2002-04-05 2005-08-16 Agilent Technologies, Inc. Jitter histogram approximation
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US20080118570A1 (en) 2006-11-20 2008-05-22 Zhi Liu Polymer coated drug-ion exchange resins and methods
WO2008122993A1 (fr) 2007-04-09 2008-10-16 Panacea Biotec Limited Formulation de microparticules enrobées à libération contrôlée
WO2009064417A2 (fr) * 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions pour le traitement d'une inflammation gastro-intestinale
US20110082221A1 (en) 2008-06-12 2011-04-07 Claire Haug In situ gelling systems as sustained delivery for front of eye
WO2011077451A2 (fr) 2009-12-22 2011-06-30 Abbott Healthcare Private Limited Composition pharmaceutique à libération contrôlée
WO2011107855A2 (fr) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Forme dosifiée sous forme de suspension liquide à libération prolongée pour une administration par voie orale
US20120009275A1 (en) 2010-06-29 2012-01-12 Asfaw Bruktawit T In-situ forming hydrogel wound dressings containing antimicrobial agents
US20130108745A1 (en) 2010-07-01 2013-05-02 Delante Health As Coated effervescent tablet
WO2012063257A2 (fr) 2010-11-10 2012-05-18 Rubicon Research Private Limited Composition à libération prolongée
CN105663078A (zh) 2016-02-01 2016-06-15 中南大学 一种泡腾片的制备方法

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
ABDELBARY ET AL., INTJPHARM., vol. 278, 2004, pages 423 - 33
ADITI ET AL., DIG DIS SCI., vol. 57, no. 10, 2012, pages 2504 - 15
AHUJA ET AL., DRUG DEV IND PHARM., vol. 23, 1997, pages 489 - 515
ASANE ET AL., PHARMAINFO.NET., vol. 5, 2007, pages 1 - 5
BANDARI ET AL., ASIAN J OF PHAM., vol. 2, 2008, pages 2 - 1 1
BIONDO ET AL., J PATHOL., vol. 209, 2006, pages 384 - 91
BODDUPALLI ET AL., JOURNAL OF ADVANCED PHARMACEUTICAL TECHNOLOGY & RESEARCH, vol. 1, no. 4, 2010, pages 381 - 387
BOURTOOM, INTERNATIONAL FOOD RESEARCH JOURNAL, vol. 15, no. 3, 2008, pages 237 - 248
CHANG ET AL., J PHARM TECHNOL., vol. 24, 2000, pages 52 - 80
CH'NG ET AL., J PHARM SCI., vol. 74, 1985, pages 399 - 05
CORREA, CANCER RES., vol. 48, no. 13, 1988, pages 3554 - 60
DAVIS ET AL., J CONTROL RELEASE, vol. 2, 1985, pages 27 - 38
DEY ET AL., J NAT BIOL MED., vol. l, no. l, 2010, pages 2 - 5
DIXON ET AL., AM J SURG PATHOL., vol. 20, 1996, pages 1161 - 81
DOBETTI ET AL., PHARM TECHNOL NAM., vol. 12, no. 9, 2001, pages 44 - 50
DONNELLY ET AL., INT J PHARM., vol. 307, 2006, pages 318 - 25
ESPOSITOCARRATTO, INT. J. PHARM., vol. 142, 1996, pages 9 - 23
GERAGHATYATTWOOD, BIOMATERIALS, vol. 21, 1997, pages 803 - 811
GUO ET AL., PHARM SCI. & TECHNOL., vol. 1, 1998, pages 254 - 261
HAGERSTROM, DISSERTATION FROM THE FACULTY OF PHARMACY, 2003
HERSHKO ET AL., BLOOD, vol. 107, no. 4, 2006, pages 1673 - 9
HERSHKO ET AL., BLOODCELLSMOLDIS, vol. 39, no. 2, 2007, pages 178 - 83
KALKAN ET AL., DIG DIS SCI., 2015
KAUSHIK ET AL., INDIAN DRUGS, vol. 4 1, no. 7, 2004, pages 410 - 12
KOIZUMI ET AL., INTJPHARM., vol. 152, 1997, pages 127 - 31
KREMSER ET AL., MAGN RESON IMAGING, vol. 26, 2008, pages 638 - 43
KULNIGG-DABSCH, WIEN MED WOCHENSCHR., vol. 166, 2016, pages 424 - 430
KUNO ET AL., J CONTROL RELEASE, vol. I 05, 2005, pages 16 - 22
LANDGREN ET AL., CANCER, vol. 117, 2011, pages 1163 - 71
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
LINDGREN ET AL., MED CLIN NORTH AM., vol. 77, 1993, pages 3 - 5
M BIONDO ET AL: "Prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis", JOURNAL OF PATHOLOGY, no. 209, 18 May 2006 (2006-05-18), pages 384 - 391, XP055623399 *
MCCARRON ET AL., JAPPL POLYM SCI., vol. 91, 2006, pages 1576 - 89
MOHIRE ET AL., RES JPHARM TECHNOL., vol. 2, 2009, pages 283 - 6
NAFEA, MEDSCAPE REFERENCE, 2014, Retrieved from the Internet <URL:http://emedicine.medscape.com/article/176036-overview>
NAGAR ET AL., JOURNAL OF APPLIED PHARMACEUTICAL SICENCE, vol. 04, 2011, pages 35 - 45
NEHA ET AL., INTERNATIONAL BULLETIN OF DRUG RESEARCH., vol. 3, no. 5, 2013, pages 69 - 82
NISHIMURA ET AL., PRODUCT DEVELOPMENT LABORATORIES, vol. 73, no. 7, 1983, pages 942 - 946
OZEKI ET AL., AAPS PHARM SCI TECH., vol. 4, 2003, pages 70
PARK ET AL., GASTROINTEST ENDOSC., vol. 77, no. 2, 2016, pages 284 - 292
PODUALPEPPAS, BIOMATERIALS, vol. 21, 2000, pages 1439 - 1450
RADKE ET AL., INT J CHEM TECH RES., vol. 1, 2009, pages 517 - 21
SHAH ET AL., ASIAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES, vol. 2, no. 8, 2012, pages 01 - 08
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556
SIPPONENPRICE, JOURNAL OF GASTROENTEROLOGY AND HEPAOLOGY, vol. 26, 2011, pages 31 - 34
STOLTE ET AL., GASTROENTEROL., vol. 15, no. 9, 2001, pages 591 - 98
SWAMY ET AL., INDIAN J PHARM SCI., vol. 71, 2009, pages I 51 - 4
SWAMY ET AL., J PHARM SCI., vol. 7, 2008, pages 1 - 5
TOH ET AL., CLIN REV ALLERGY IMMUNOL., vol. 42, 2012, pages 269 - 78
TOH ET AL., IMMUNOLTODAY., vol. 21, no. 7, 2000, pages 348 - 54
TOH, AUTOIMMUN REV., vol. 13, 2014, pages 459 - 62
TORBENSON ET AL., MOD PATHOL., vol. 15, no. 2, 2002, pages 102 - 109
YANG ET AL., J PHARM PHARMACOL., vol. 56, 2004, pages 429 - 36

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP7202070B2 (ja) ポリペプチドおよび／またはタンパク質を含む固体塊の製作のための薬学的組成物および方法
US9980902B2 (en) Method for treating intestinal fibrosis
JP4088420B2 (ja) 多糖類を利用した大腸選択性薬物伝達組成物および医薬製剤
Ahuja et al. Mucoadhesive drug delivery systems
CA2765033C (fr) Procedes de traitement de troubles gastro-intestinaux
JP4216912B2 (ja) 結腸送逹のための多層腸溶性ポリマーコーティングを有するビサコジル投与形態
EP3500264A1 (fr) Méthode de traitement de l&#39;oesophagite éosinophile
KR20170016970A (ko) 피부 또는 점막에 활성 물질의 특정 용량을 투여하기 위한 전기수력학적으로 수득된 섬유를 포함하는 조성물
JP3725539B2 (ja) ビサコジル剤形
BG65502B1 (bg) Фармацевтичен състав за лечение на остри неразположения и неговото използване
RU2678695C2 (ru) Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита
JP2010534721A (ja) パルス型胃滞留性製剤
JP2001500879A (ja) 可溶性に乏しい薬物および不溶性の物質の制御放出のための胃滞留性経口薬物投薬形態
JP2009536147A (ja) 経口経粘膜送達用の生体接着性薬調合物
JPS5892610A (ja) 経口用放出調整複合単位製剤
JP2010047607A (ja) グルココルチコイドの部位時間制御胃腸放出作用を有する錠剤
JP2008516893A (ja) 多層錠剤および生体接着性剤形
JP5134955B2 (ja) 活性成分の部位時間制御胃腸放出作用を有する錠剤
Khan et al. Review on mucoadhesive drug delivery system: novel approaches in modern era
KR101727847B1 (ko) 글리코사미노글리칸을 포함하는 약제학적 제제
JP2018065776A (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
WO2020011938A1 (fr) Glucocorticoïdes pour le traitement topique de la gastrite auto-immune
JP6532529B2 (ja) ミソプロストール分散性錠剤
EP1100481B1 (fr) Formulations pharmaceutiques servant a traiter la maladie intestinale inflammatoire
US20200214985A1 (en) Pharmaceutical composition particles, orally disintegrating preparation containing same, and method for producing pharmaceutical composition particles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19737121

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19737121

Country of ref document: EP

Kind code of ref document: A1